front |1 |2 |3 |4 |5 |6 |7 |8 |9 |10 |11 |12 |13 |14 |15 |16 |17 |18 |19 |20 |21 |22 |23 |24 |25 |26 |27 |28 |29 |30 |31 |32 |33 |34 |35 |36 |37 |38 |39 |40 |41 |42 |43 |44 |45 |46 |47 |48 |review |
30% loss to follow-up Norethindrone 35 mic Problems: Limited details about trial, indicates blinding but not how it was done, no allocation concealment mentioned. No sample size calc, no numerical results or graphs. No mention of discontinuation, loss to follow-up or exclusions. Graphs not labeled. |